Resources

Join Winston Taylor and Raymond James on 23rd September 2026 in London, as we bring together leaders who've built, scaled, and exited growth-stage businesses. A sharp, practical discussion on the routes to growth, liquidity, and exit.

UK Life Sciences Innovation Signals Report (H1 2026) explores how effectively the UK is converting scientific innovation into commercial growth, healthcare adoption, and patient impact. The report assesses three critical areas: Capital, Capability, and Conversion, revealing that while investment remains strong (£2.83bn raised in H1 2026) and research capabilities continue to improve, the sector's biggest challenge is turning innovation into widespread adoption across healthcare systems and markets. Key findings show that funding is increasingly concentrated in a small number of high-conviction companies, regulatory and clinical trial processes are becoming more efficient, and NHS adoption of new innovations is improving but remains inconsistent. The report provides valuable insights for founders, CFOs, investors, and industry leaders looking to understand the trends, opportunities, and challenges shaping the future of UK life sciences.

Precision BioSearch partners with Cytospire Therapeutics to appoint Sumeet Ambarkhane as CMO

Pioneer Group and Oxford Properties have announced that Syncona Investment Management Ltd (SIML), a leading life science investment manager, is moving into Victoria House, a leading hub for life sciences in London.

IMU Biosciences has formed a strategic partnership with Eurofins Transplant Genomics, with an exclusive licensing agreement to give the company access to IMU’s proprietary HD Immunology platform for transplant-related clinical development programmes.

What do the six most dangerous hospital superbugs have in common, and what makes each one distinct? MORF-Bio's live webinar compares all six genomes to find out.

Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive results from the Brainomix AI-driven quantitative analysis of HRCT imaging data in Endeavor's Phase 2a trial of taladegib in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) Conference in Barcelona.

How recent British Business Bank commitments and BIA member milestones are keeping UK life sciences momentum strong

Stevenage Bioscience Catalyst Board appoints Andrew Waters as Chief Executive Officer

Tangram Therapeutics announces progression to patient cohorts in Phase 1/2 RESTORE-MASH trial of TGM-312 and appointment of Dr Sonya Montgomery as Chief Development Officer

Coulter Partners successfully led a search assignment for NRG Therapeutics Ltd. and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.

Foventa has strengthened its management team with a new CMO Dr Zaiba Malik and CFO Julia Jones as the company prepares for a Series A funding round to take lead asset FOV407 into a Phase IIb trial.

MyAmici and My Green Lab announce collaboration to support more sustainable lab purchasing. The integration helps life-science labs consider environmental impact alongside price and availability with other purchasing solutions to aid sustainability.

Imagine a world where diabetic patients no longer lose their sight. Foventa are already trialling a simple eyedrop that could make this a reality. Previously Exonate, Foventa are now Phase II ready and about to commence a Series A funding round.

LinkGevity is working with Health Innovation East, the NHS innovation arm for the East of England, to advance the clinical pathway for its first-in-class Anti-Necrotic™ therapeutic approach.

LinkGevity’s Dr Carina Kern and Serena Kern-Libera discuss new approach to age-related disease

LinkGevity CEO Dr Carina Kern contributes to new Springer Nature volume on longevity science